Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia
Mutations involving epigenetic regulators (TET2~60% and ASXL1~40%) and splicing components (SRSF2~50%) are frequent in chronic myelomonocytic leukemia (CMML). On a 27-gene targeted capture panel performed on 175 CMML patients (66% males, median age 70 years), common mutations included: TET2 46%, ASX...
Main Authors: | Patnaik, M M, Lasho, T L, Vijayvargiya, P, Finke, C M, Hanson, C A, Ketterling, R P, Gangat, N, Tefferi, A |
---|---|
Format: | Online |
Language: | English |
Published: |
Nature Publishing Group
2016
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742630/ |
Similar Items
-
Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance
by: Patnaik, M M, et al.
Published: (2016) -
SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML
by: Laborde, R R, et al.
Published: (2013) -
ASXL1 mutated chronic myelomonocytic leukemia in a patient with familial thrombocytopenia secondary to germline mutation in ANKRD26
by: Perez Botero, J, et al.
Published: (2015) -
Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia
by: Lasho, T L, et al.
Published: (2015) -
Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia
by: Cui, Yajuan, et al.
Published: (2015)